Literature DB >> 3101497

Hypophosphatemic osteomalacia and adult Fanconi syndrome due to light-chain nephropathy. Another form of oncogenous osteomalacia.

D S Rao, A M Parfitt, A R Villanueva, P J Dorman, M Kleerekoper.   

Abstract

Two patients, one with myeloma (Patient 1) and the other with probable chronic lymphocytic leukemia (Patient 2), had reduced renal tubular phosphate reabsorption in the absence of hyperparathyroidism together with other features of the Fanconi syndrome, as consequences of the nephropathy associated with light-chain proteinuria. Both patients had hypophosphatemic osteomalacia, demonstrated for the first time in this condition by iliac bone histomorphometry after in vivo double tetracycline labeling, despite absence of bone pain or Looser zones. Neither patient was vitamin D-depleted, but plasma calcitriol level was normal in Patient 1 and low in Patient 2; only the latter patient had severe muscle weakness. Complete histologic correction of osteomalacia was achieved by treatment in accordance with the biochemical defects--oral phosphate therapy alone in Patient 1 and combined with calcitriol in Patient 2. Both patients are now symptom-free, five and three years after the initial diagnosis of bone disease and hematogenous malignancy. Thirteen previous instances of the same form of osteomalacia were reviewed; in most cases, the Fanconi syndrome developed before its probable cause became apparent. The Fanconi syndrome has also been reported in two cases of osteomalacia due to mesenchymal tumor, but not in osteomalacia associated with prostatic carcinoma. Light-chain nephropathy and consequent renal tubular dysfunction appears to be a third form of oncogenous osteomalacia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3101497     DOI: 10.1016/0002-9343(87)90081-7

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  16 in total

Review 1.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

Review 2.  The life and times of the Enterococcus.

Authors:  B E Murray
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

3.  Glucosuria without diabetes: key to the diagnosis of fragility fractures due to Fanconi syndrome.

Authors:  Lilluck F Alacapa; Mark Anthony Santiago Sandoval; Coralie Therese D Dimacali; Nathaniel Jr S Orillaza
Journal:  BMJ Case Rep       Date:  2018-05-07

4.  Ciprofloxacin decreases the rate of ethanol elimination in humans.

Authors:  J Tillonen; N Homann; M Rautio; H Jousimies-Somer; M Salaspuro
Journal:  Gut       Date:  1999-03       Impact factor: 23.059

5.  Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

6.  Life threatening hypophosphataemia in a patient with Philadelphia chromosome-positive chronic myelogenous leukaemia in acute blastic crisis.

Authors:  P Ra'anani; M Lahav; M Prokocimer; L Poles; E Theodor
Journal:  Postgrad Med J       Date:  1992-04       Impact factor: 2.401

7.  In vitro activities of enoxacin, enrofloxacin, sparfloxacin, and ciprofloxacin against Escherichia coli strains isolated from diarrheic lambs and kids.

Authors:  D Cid; S Piriz; J A Ruiz-Santa-Quiteria; J Valle; S Garcia; S Vadillo; R de la Fuente
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

8.  Single-dose and three-day regimens of ofloxacin versus trimethoprim-sulfamethoxazole for acute cystitis in women.

Authors:  T M Hooton; C Johnson; C Winter; L Kuwamura; M E Rogers; P L Roberts; W E Stamm
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

Review 9.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

10.  Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits.

Authors:  Kathryn M Thrailkill; R Clay Bunn; Sasidhar Uppuganti; Philip Ray; Iuliana Popescu; Evangelia Kalaitzoglou; John L Fowlkes; Jeffry S Nyman
Journal:  Bone       Date:  2020-09-02       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.